Caspases and neurodegeneration: On the cutting edge of new therapeutic approaches

Clinical Genetics

Volumn 57, Issue 1, 2000, Pages 1-10

  Wellington, Cheryl L ^a   Hayden, Michael R ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Centre for Molecular Medicine and Therapeutics   (Canada)

Author keywords

Caspases; Neurodegeneration; Therapeutic approaches

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ANDROGEN RECEPTOR; ATAXIN 3; ATROPHIN 1; CASPASE; HUNTINGTIN; POLYGLUTAMINE; PRESENILIN 1; PROTEIN; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; APOPTOSIS; CARBOXY TERMINAL SEQUENCE; CELL DEATH; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; APOPTOSIS; CASPASES; HUMANS; HUNTINGTON DISEASE; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; PRESENILIN-1; PRESENILIN-2;

ANIMALIA;

EID: 0033953015     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.2000.570101.x     Document Type: Review

References (63)

1. Wolf BB, Green DR. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem 1999: 274: 20049-20052.
2. Li H, Yuan J. Deciphering the pathways of life and death. Curr Opin Cell Biol 1999: 11: 261-266.
3. Porter AG, Ng P, Janicke RU. Death substrates come alive. BioEssays 1997: 19: 501-507.
4. Thornberry NA, Lazebnik YA. Caspases: enemies within. Science 1998: 281: 1312-1316.
5. Thornberry NA, Rano TA, Peterson EP et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem 1997: 272: 17907-17911.
6. Rano TA, Timkey T, Peterson EP et al. A combinatorial approach for determining protease specificities: application to interleukin-1beta converting enzyme (ICE). Chem Biol 1997: 4: 149-155.
7. Yuan J-Y, Shaham S, Ledoux S, Ellis HJM, Horvitz HR. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme. Cell 1993: 75: 641-652.
8. Nuñez G, Benedict MA, Hu Y, Inohara N. Caspases: the proteases of the apoptotic pathway. Oncogene 1998: 17: 3237-3245.
9. Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ 1999: 6: 99-104.
10. Hayden MR. Huntington's Chorea. London. Berlin, Heidelberg: Springer-Verlag, 1981.
11. Harper PS. Huntington's Disease. London, Philadelphia: W.B. Saunders, 1991.
12. Wellington CL, Brinkman RR, O'Kusky JR, Hayden MR. Toward understanding the molecular pathology of Huntington's disease. Brain Pathol 1997: 7: 979-1002.
13. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985: 44: 559-577.
14. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993: 72: 971-983.
15. Andrew SE, Goldberg YP, Kremer B et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington disease. Nat Genet 1993: 4: 398-403.
16. Duyao M, Ambrose C, Myers R et al. Trinucleotide repeat length instability and age of onset in Huntington disease. Nat Genet 1993: 4: 387-392.
17. Martindale D, Hackam AS, Wieczorek A et al. Length of the protein and polyglutamine tract influence localization and frequency of intracellular aggregates of huntingtin. Nat Genet 1998: 18: 150-154.
18. Hackam AS, Singaraja R, Wellington CL et al. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol 1998: 141: 1097-1105.
19. Cooper JK, Schilling G, Peters MF et al. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet 1998: 7: 783-790.
20. Goldberg YP, Nicholson DW, Rasper DM et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet 1996: 13: 442-449.
21. Wellington CL, Ellerby LM, Hackam AS et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutumine tract. J Biol Chem 1998: 273: 9158-9167.
22. Wellington CL, Hayden MR. Of molecular interactions, mice and mechanisms: new insights into Huntington's disease. Curr Opin Neurol 1997: 10: 291-298.
23. Kim M, Lee H-S, LaForet G et al. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci 1999: 19: 964-973.
24. Sanchez I, Xu C-J, Juo P, Kakizuka A, Blenis J, Yuan J. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 1999: 22: 623-633.
25. Ona VO, Li M, Vonsattel J et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999: 399: 263-267.
26. Mangiarini L, Sathasivam K, Seller M et al. Exon 1 of the HD Gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996: 87: 493-506.
27. Wellington CL, Ellerby LM, Hackam AS et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 1998: 273: 9158-9167.
28. Ellerby LM, Andrusiak RL, Wellington CL et al. Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. J Biol Chem 1999: 274: 8730-8736.
29. Ellerby LM, Hackam AS, Propp SS et al. Kennedy's disease: caspase cleavege of the androgen receptor is a crucial event in cytotoxicity. J Neurochem 1999: 72: 185-195.
30. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999: 399 (Suppl.): A23-A31.
31. Wolfe M, Xia W, Ostaszewski BL, Dieh TS, Kimberley WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature 1999: 398: 513-517.
32. DeStrooper BD, Annaert W, Cupers P et al. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracelular domain. Nature 1999: 398: 518-522.
33. Struh G, Greenwald I. Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature 1999: 398: 522-525.
34. Ye Y, Lukinova N, Fortina ME. Neurogenic phenotypes and altered Notch processing on Drosophilia Presenilin mutants. Nature 1999: 398: 525-529.
35. Davis JA, Naruse S, Chen H et al. An Alzheimer's disease-linked PS1 variant rescues the developmental abnormalities of PS1-deficient embryos. Neuron 1998: 20: 603-609.
36. Quian S, Jiang P, Guan XM et al. Mutant human presenilin 1 protects presenilin 1 null mouse against embryonic lethality and elevates Aβ1-42 43 expression. Neuron 1998: 20: 611-617.
37. DeStrooper B, Saftig P, Craessaeerts K et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998: 391: 387-390.
38. Xia W, Zhang J, Ostaszewski BL et al. Presenilin 1 regulates the processing of β-amyloid precursor protein C-terminal fragments and the generation of amyloid β-protein in endoplasmic reticulum and Golgi. Biochemistry 1998: 37: 16465-16471.
39. Selkoe DJ. Cell biology of the amyloid β-protein precursoe and the mechanism of Alzheimer's disease. Annu Rev Cell Biol 1999: 10: 373-403.
40. Zheng H, Jiang M, Trumbauer ME et al. beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 1995: 81: 525-531.
41. Gervais FG, Xu D, Robertson GS et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyoid-b precursor protein and amyloidogenic Aβ peptide formation. Cell 1999: 97: 395-406.
42. Pellegrini L, Passer BJ, Tabaton M, Ganjei JK, D'Adamio L. Alternative, non-secretase processing of Alzheimer's β-amyloid precursor protein during apoptosis by caspase-6 and -8. J Biol Chem 1999: 274: 21011-21016.
43. LeBlanc A, Liu J, Goodyer C, Bergeron C, Hammond J. Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer's Disease. J Biol Chem 1999: 274: 23426-23436.
44. Weidemann A, Paliga K, Drrwang U et al. Proteolytic processing of the Alzheimer's disease amyloid precursor protein within its cytoplasmic domain by caspase-like proteases. J Biol Chem 1999: 274: 5823-5829.
45. Nicholson DW. ICE CED3-like proteases as therapeutic targets for the control of inappropriate apoptosis. Nat Biotech 1996: 14: 297-301.
46. Borg JP, Yang Y, De Taddeo-Borg M, Margolis B, Turner RS. The X11α protein slows cellular amyloid precursor protein processing and reduces Aβ40 and Aβ42 secretion. J Biol Chem 1998: 273: 14761-14766.
47. Citron M, Oltersdorf T, Haass C et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 1992: 360: 672-674.
48. Nishimura M, Yu G, St. George-Hyslop P. Biology of presenilins as causative molecules for Alzheimer disease. Clin Genet 1999: 55: 219-225.
49. Vito P, Ghayur T, D'Adamio L. Generation of anti-apoptotic presenilin-2 polypeptides by alternative transcription, proteolysis, and caspase-3 cleavage. J Biol Chem 1997: 272: 28315-28320.
50. Loetscher H, Deuschle U, Brockhaus M et al. Presenilins are processed by caspase-type proteases. J Biol Chem 1997: 272: 20655-20659.
51. Grunberg J, Walter J, Loetscher H et al. Alzheimer's disease associated presenilin-1 holoprotein and its 18 20 kDa C-terminal fragment are death substrates for proteases of the caspase family. Biochemistry 1998: 37: 2263-2270.
52. Kim TW, Pettingell WH, Jung YK, Kovacs DM, Tanzi RE. Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science 1997: 277: 373-376.
53. Wolozin B, Iwasaki K, Vito P et al. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science 1996: 274: 1710-1713.
54. Vito P, Wolozin B, Ganjei JK, Iwasaki K, Lacuna E, D'Adamio L. Requirement of the familial Alzheimer's disease PS2 for apoptosis: opposing effect of ALG-3. J Biol Chem 1996: 271: 31025-31028.
55. Walter J, Grunberg J, Schindzielorz A, Haass C. Proteolytic fragments of the Alzheimer's disease associated presenilins-1 and -2 are phosphorylated in vitro by distinct cellular mechanisms. Biochemistry 1998: 37: 5961-5967.
56. Walter J, Schindzielorz A, Grunberg J, Haass C. Phosphorylation of presenilin-2 regulates its cleavage by caspases and retard progression of apoptosis. Proc Natl Acad Sci USA 1999: 96: 1391-1396.
57. +)-binding protein ALG-2 and Alzheimer's disease gene ALG-3. Science 1996: 271: 521-525.
58. Hackam AS, Wellington CL, Hayden MR. The fatal attraction of polyglutamine-containing proteins. Clin Genet 1998: 53: 233-242.
59. Kakizuka A. Protein precipitation: a common etiology in neurodegenerative disorders? Trends Neurosci 1998: 14: 396-402.
60. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997: 56: 321-339.
61. Hodgson JG, Agopyan N, Gutekunst C-A et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytophismic toxicity, and selective striatal neurodegeneration. Neuron 1999: 23: 181-192.
62. Ikeda H, Yamaguchi M, Sugai S, Aze Y, Narumiya S, Kakizuka A. Expanded polyglutamine in the Machado Joseph disease protein induces cell death in vitro and in vivo. Nat Genet 1996: 13: 196-202.
63. Wellington CL, Singaraja R, Ellerby L et al. Inhibition of caspase cleavage of huntingtin protects neurons from toxicity and aggregate formation. Am J Human Genet 1999: 65 (4): A4.